Sigachi IndustriesQ2 FY25

Sigachi Industries Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹28.61P/E: 43.7Market Cap: ₹1.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Sigachi Industries expects top-line growth of approximately 30% for the current financial year, driven by added capacities and new products like PureCoat and UltraMod.
  • The company has a sustainable revenue growth outlook of 25%-30% annually over the next few years.
  • MCC segment grew 15%-20%, outpacing the global MCC growth of about 10%, with market share gains from better pricing, service, and a wide product range.
  • API segment capacity is being expanded from 100 KL to 250 KL, with full utilization expected by mid-FY26. API revenue share is targeted to reach around 30% of total revenue this year.
  • The CCS and O&M segments are also poised for growth with ongoing and planned capex, contingent on regulatory approvals.
  • The Gulf operations and Middle East ventures are expected to contribute revenues starting next financial year.
  • Overall, management is confident of maintaining or improving EBITDA margins alongside revenue growth.

See what Sigachi Industries management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
- Sigachi Industries is currently seeking an umbrella approval for raising funds through Foreign Currency Convertible Bonds (FCCBs), which requires RBI, SEBI, and shareholder approvals. - The company is not planning to raise all the funds immediately but will tap the FCCB route as needed for growth. - The FCCBs would carry a coupon rate and are not purely equity dilution at this moment. - The management emphasizes careful cost-benefit analysis before any new capex, implying funding will be raised only if it benefits the company. - There is no mention of a current definitive equity fundraising; the FCCB approval is preparatory. - Promoter shareholding will increase after full payment of preferential shares; no promoter selling or dilution is planned now. - Any new fundraising will be executed through the best available options, balancing loan and equity components depending on opportunity. Thus, while immediate fundraising is not underway, the company has structured approvals and intent for future debt/equity funding as required.

See what Sigachi Industries management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing capex includes API expansion and CCS expansion with timelines around 12 to 18 months.
  • New coating product capacities (PureCot and Ultramod) have commenced operations and are in sampling phase.
  • Plan to increase MCC capacity soon due to 50% utilization of current expanded capacity and strong demand.
  • Future MCC capacity expansions are likely within 2 to 3 years, driven by demand and consumption growth.
  • Capex also planned for setting up a manufacturing plant in the USA to reduce freight and logistics costs.
  • Company is seeking umbrella approval for raising funds via unsecured convertible bonds (FCCB) to support growth capex.
  • CCS plant project delayed due to pending pollution control board approval; progress expected once approvals are received.
  • Focus on incremental capex only after thorough cost-benefit analysis to ensure it supports business growth.

Track Sigachi Industries — get its next earnings analysis in your feed

How does Sigachi Industries rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSigachi Industries
Rev 2Mar 3

How does Sigachi Industries rank in Pharmaceuticals & Biotechnology?

Compare Sigachi Industries against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →